Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Compugen Ltd.
  6. Summary
    CGEN   IL0010852080

COMPUGEN LTD.

(CGEN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/19/2022 01/20/2022 01/21/2022 01/24/2022 01/25/2022 Date
3.81(c) 3.81(c) 3.66(c) 3.63(c) 3.59(c) Last
964 717 1 218 192 1 387 172 1 590 993 1 388 028 Volume
+0.26% 0.00% -3.94% -0.82% -1.10% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 6,86 M - -
Net income 2021 -37,2 M - -
Net Debt 2021 - - -
P/E ratio 2021 -8,13x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -63,6 M - -
Net Debt 2022 - - -
P/E ratio 2022 -5,12x
Yield 2022 -
Capitalization 310 M 310 M -
Capi. / Sales 2021 45,1x
Capi. / Sales 2022 -
Nbr of Employees 68
Free-Float 94,2%
More Financials
Company
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune... 
More about the company
Ratings of Compugen Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about COMPUGEN LTD.
01/18Compugen Awarded US Patent for Method of Use of Cancer Drug Candidate
MT
01/18Compugen Expands COM701 Intellectual Property Portfolio with New U.S. Patent Covering T..
PR
01/18Compugen Expands COM701 Intellectual Property Portfolio with New U.S. Patent Covering T..
CI
2021Compugen Presents Preliminary Translational Data Demonstrating Immune Activation in the..
PR
2021Compugen Wins Fortinet Achievement Award at NSE XPERTS Summit 2021
AQ
2021Oppenheimer Adjusts Compugen PT to $17 From $19, Maintains Outperform Rating
MT
2021COMPUGEN : Q3 Earnings Snapshot
AQ
2021Compugen Narrows Net Loss in Q3, Revenue Gains on Milestone Payment
MT
2021Press Release dated November 12, 2021 – “Compugen Presents Preliminary Resu..
PU
2021Compugen Announces Collaboration Expansion with Bristol Myers Squibb alongside $20 Mill..
PU
2021Compugen Presents Preliminary Results from Phase 1 Dose Escalation Monotherapy Study of..
PR
2021Compugen Presents Initial Translational Data Supporting the Differentiation of PVRIG Co..
PR
2021Compugen Presents Preliminary Results from Phase 1/2 Dose Escalation Study of COM701 wi..
PR
2021Compugen Reports Third Quarter 2021 Results
PR
2021Compugen Presents Initial Translational Data Supporting the Differentiation of PVRIG Co..
CI
More news
News in other languages on COMPUGEN LTD.
01/18Compugen obtient un brevet américain pour une méthode d'utilisation d'un médicament can..
01/18Compugen élargit le portefeuille de propriété intellectuelle de COM701 avec un nouveau ..
2021Compugen réduit sa perte nette au troisième trimestre et augmente ses revenus grâce à u..
2021Les actions du secteur de la santé toujours en baisse juste avant la clôture de jeudi
2021Les actions du secteur de la santé en baisse jeudi
More news
Analyst Recommendations on COMPUGEN LTD.
More recommendations
Chart COMPUGEN LTD.
Duration : Period :
Compugen Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends COMPUGEN LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 3,59 $
Average target price 20,57 $
Spread / Average Target 473%
EPS Revisions
Managers and Directors
Anat Cohen-Dayag President, Chief Executive Officer & Director
Ari Krashin Chief Operating & Financial Officer
Paul Jai Sekhri Chairman
Henry Adewoye Chief Medical Officer
Arie Ovadia Director
Sector and Competitors
1st jan.Capi. (M$)
COMPUGEN LTD.-16.51%310
MODERNA, INC.-38.07%63 777
LONZA GROUP AG-19.59%49 711
IQVIA HOLDINGS INC.-13.62%46 556
SEAGEN INC.-16.20%23 689
ICON PUBLIC LIMITED COMPANY-17.32%20 842